Gary Jacob
Chief Executive Officer chez OKYO PHARMA LIMITED
Fortune : 69 885 $ au 31/03/2024
Profil
Gary S.
Jacob founded Synergy Pharmaceuticals, Inc. in 2008, where he worked as Chairman, President & Chief Executive Officer from 2013 to 2017.
Dr. Jacob also founded Synergy Pharmaceuticals LLC, where he worked as Executive Chairman from 2017 to 2018.
Dr. Jacob also currently works at OKYO Pharma Ltd., as Chief Executive Officer & Executive Director from 2021 and Actavia Life Sciences, Inc., as Independent Director from 2020.
Dr. Jacob also formerly worked at Callisto Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2004 to 2013, Pawfect Foods, Inc., as President, Chief Executive Officer & Director in 2008, Immuron Ltd., as CEO, Non-Executive Director & Managing Director from 2019 to 2020, Hepion Pharmaceuticals, Inc., as Chairman from 2014 to 2024, Synergy DE, as Chairman in 2008, Monsanto Co., as Director-Functional Genomics, Science & Technology from 1997 to 1998, Cardiff Oncology, Inc., as Independent Director from 2012 to 2021, G.D.
Searle LLC, as Glycobiology Director from 1990 to 1997, Virpax Pharmaceuticals, Inc., as Independent Director from 2020 to 2022, and the University of Oxford, as Manager-Searle Glycobiology Group in 1990.
Dr. Jacob received his doctorate degree from the University of Wisconsin and undergraduate degree from the University of Missouri-St. Louis.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OKYO PHARMA LIMITED
0,14% | 28/07/2023 | 45 883 ( 0,14% ) | 68 366 $ | 31/03/2024 |
| 19/02/2024 | 610 ( 0,01% ) | 1 519 $ | 31/03/2024 | |
| 15/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Gary Jacob
| Sociétés | Poste | Début |
|---|---|---|
| ACTAVIA LIFE SCIENCES, INC. | Director/Board Member | 23/12/2020 |
| OKYO PHARMA LIMITED | Chief Executive Officer | 07/01/2021 |
Anciens postes connus de Gary Jacob
| Sociétés | Poste | Fin |
|---|---|---|
| HEPION PHARMACEUTICALS, INC. | Chief Executive Officer | 19/03/2014 |
| VIRPAX PHARMACEUTICALS, INC. | Director/Board Member | 25/07/2022 |
| IMMURON LIMITED | Chief Executive Officer | 25/03/2020 |
| SYNERGY PHARMACEUTICALS INC | Chief Executive Officer | 19/12/2017 |
| Synergy Pharmaceuticals, Inc. /Old/ | Chief Executive Officer | 01/10/2017 |
Formation de Gary Jacob
| University of Wisconsin | Doctorate Degree |
| University of Missouri-St. Louis | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| OKYO PHARMA LIMITED | Health Technology |
| HEPION PHARMACEUTICALS, INC. | Health Technology |
| CARDIFF ONCOLOGY, INC. | Health Technology |
| IMMURON LIMITED | Health Technology |
| ACTAVIA LIFE SCIENCES, INC. | Health Technology |
| VIRPAX PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Monsanto Co.
 Monsanto Co. Wholesale DistributorsDistribution Services Monsanto Co. engages in the provision of agricultural products to farmers. It provides other seed companies with genetic material and biotechnology traits for their seed brands. The company was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO. | Distribution Services |
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | Health Technology |
| Pawfect Foods, Inc. | Retail Trade |
| Synergy Pharmaceuticals, Inc. /Old/ | Health Technology |
| G.D. Searle LLC | |
| Synergy DE | |
Synergy Pharmaceuticals LLC
 Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |
